Literature DB >> 24090706

Fluctuations in phenylalanine concentrations in phenylketonuria: a review of possible relationships with outcomes.

Maureen Cleary1, Friedrich Trefz, Ania C Muntau, François Feillet, Francjan J van Spronsen, Alberto Burlina, Amaya Bélanger-Quintana, Maria Giżewska, Christoph Gasteyger, Esther Bettiol, Nenad Blau, Anita MacDonald.   

Abstract

Fluctuations in blood phenylalanine concentrations may be an important determinant of intellectual outcome in patients with early and continuously treated phenylketonuria (PKU). This review evaluates the studies on phenylalanine fluctuations, factors affecting fluctuations, and if stabilizing phenylalanine concentrations affects outcomes, particularly neurocognitive outcome. Electronic literature searches of Embase and PubMed were performed for English-language publications, and the bibliographies of identified publications were also searched. In patients with PKU, phenylalanine concentrations are highest in the morning. Factors that can affect phenylalanine fluctuations include age, diet, timing and dosing of protein substitute and energy intake, dietary adherence, phenylalanine hydroxylase genotype, changes in dietary phenylalanine intake and protein metabolism, illness, and growth rate. Even distribution of phenylalanine-free protein substitute intake throughout 24h may reduce blood phenylalanine fluctuations. Patients responsive to and treated with 6R-tetrahydrobiopterin seem to have less fluctuation in their blood phenylalanine concentrations than controls. An increase in blood phenylalanine concentration may result in increased brain and cerebrospinal fluid phenylalanine concentrations within hours. Although some evidence suggests that stabilization of blood phenylalanine concentrations may have benefits in patients with PKU, more studies are needed to distinguish the effects of blood phenylalanine fluctuations from those of poor metabolic control.
© 2013.

Entities:  

Keywords:  6R-tetrahydrobiopterin; BH(4); ECT; HPA; Hyperphenylalaninemia; IDC; IQ; LNAA; PAH; PKU; Phenylalanine fluctuations; Phenylketonuria; SD; SEE; Sapropterin; Tyr; WISC; Wechsler Intelligence Scale for Children; early and continuously treated; hyperphenylalaninemia; index of dietary control; intelligence quotient; large neutral amino acid; phenylalanine hydroxylase; phenylketonuria; standard deviation; standard error of the estimate; tyrosine

Mesh:

Substances:

Year:  2013        PMID: 24090706     DOI: 10.1016/j.ymgme.2013.09.001

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  22 in total

1.  Variability in phenylalanine control predicts IQ and executive abilities in children with phenylketonuria.

Authors:  Anna Hood; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desirée A White
Journal:  Mol Genet Metab       Date:  2014-01-31       Impact factor: 4.797

2.  Phenylalanine Monitoring via Aptamer-Field-Effect Transistor Sensors.

Authors:  Kevin M Cheung; Kyung-Ae Yang; Nako Nakatsuka; Chuanzhen Zhao; Mao Ye; Michael E Jung; Hongyan Yang; Paul S Weiss; Milan N Stojanović; Anne M Andrews
Journal:  ACS Sens       Date:  2019-11-01       Impact factor: 7.711

3.  Dietary patterns, cost and compliance with low-protein diet of phenylketonuria and other inherited metabolic diseases.

Authors:  T Mlčoch; R Puda; P Ješina; M Lhotáková; Š Štěrbová; T Doležal
Journal:  Eur J Clin Nutr       Date:  2017-06-28       Impact factor: 4.016

4.  A retrospective analysis of metabolic control in children with PKU in the COVID-19 era.

Authors:  Dóra Becsei; Erika Kiss; Ildikó Szatmári; András Arató; György Reusz; Attila J Szabó; János Bókay; Petra Zsidegh
Journal:  Mol Genet Metab Rep       Date:  2022-07-08

5.  Improved Measurement of Brain Phenylalanine and Tyrosine Related to Neuropsychological Functioning in Phenylketonuria.

Authors:  Susan E Waisbren; Sanjay P Prabhu; Patricia Greenstein; Carter Petty; Donald Schomer; Vera Anastasoaie; Kalin Charette; Daniel Rodriguez; Sai Merugumala; Alexander P Lin
Journal:  JIMD Rep       Date:  2016-09-28

Review 6.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

Review 7.  Seeding of proteins into amyloid structures by metabolite assemblies may clarify certain unexplained epidemiological associations.

Authors:  Dorin Sade; Shira Shaham-Niv; Zohar A Arnon; Omid Tavassoly; Ehud Gazit
Journal:  Open Biol       Date:  2018-01       Impact factor: 6.411

8.  Effect of dietary regime on metabolic control in phenylketonuria: Is exact calculation of phenylalanine intake really necessary?

Authors:  Carmen Rohde; Alena Gerlinde Thiele; Ulrike Och; Katrin Schönherr; Uta Meyer; Stefanie Rosenbaum-Fabian; Cornelia Maddalon; Sabine Matzken; Holger Blessing; Frauke Lang; Monika Jörg-Streller; Skadi Beblo
Journal:  Mol Genet Metab Rep       Date:  2015-10-22

9.  Health economic burden of patients with phenylketonuria (PKU) - A retrospective study of German health insurance claims data.

Authors:  Friedrich Trefz; Ania C Muntau; Kim M Schneider; Julia Altevers; Christian Jacob; Sebastian Braun; Wolfgang Greiner; Ashok Jha; Mohit Jain; Ignacio Alvarez; Paul Lane; Claudia Zeiss; Frank Rutsch
Journal:  Mol Genet Metab Rep       Date:  2021-05-13

10.  The challenge of long-term tetrahydrobiopterin (BH4) therapy in phenylketonuria: Effects on metabolic control, nutritional habits and nutrient supply.

Authors:  Alena G Thiele; Carmen Rohde; Ulrike Mütze; Maria Arelin; Uta Ceglarek; Joachim Thiery; Christoph Baerwald; Wieland Kiess; Skadi Beblo
Journal:  Mol Genet Metab Rep       Date:  2015-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.